MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Behavioral Pharmacology of THC and Beta-Myrcene

Phase 1
Not yet recruiting
Conditions
Cannabis Use
Interventions
Drug: Beta-Myrcene
Drug: Placebo
First Posted Date
2022-06-27
Last Posted Date
2025-04-10
Lead Sponsor
Johns Hopkins University
Target Recruit Count
32
Registration Number
NCT05432284
Locations
🇺🇸

Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

Phase 2
Suspended
Conditions
Cannabis
Migraine
THC
Interventions
First Posted Date
2022-06-22
Last Posted Date
2024-04-30
Lead Sponsor
University of California, San Diego
Target Recruit Count
20
Registration Number
NCT05427630
Locations
🇺🇸

Center for Pain Medicine, UC San Diego, La Jolla, California, United States

Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain

Phase 2
Recruiting
Conditions
Diabetic Neuropathic Pain
Peripheral Neuropathic Pain
Interventions
First Posted Date
2022-04-28
Last Posted Date
2025-03-12
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
320
Registration Number
NCT05351801
Locations
🇺🇸

VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States

🇺🇸

VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States

🇺🇸

Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States

and more 2 locations

Dronabinol After Arthroscopic Surgery

Phase 3
Recruiting
Conditions
Knee Osteoarthritis
Loose Body Knee
Knee Injuries
Meniscus Tear
Synovitis of Knee
Knee Ligament Injury
Chondral Injury of Left Knee
Chondral Injury of Right Knee
Interventions
Drug: Placebo
First Posted Date
2022-04-19
Last Posted Date
2025-04-29
Lead Sponsor
Northwestern University
Target Recruit Count
30
Registration Number
NCT05335252
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

THC Effects on Glucose in Type 2 Diabetes

Phase 1
Recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: Placebo
First Posted Date
2022-04-11
Last Posted Date
2025-05-07
Lead Sponsor
University of California, San Diego
Target Recruit Count
30
Registration Number
NCT05322213
Locations
🇺🇸

UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States

Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC

Phase 1
Completed
Conditions
Behavioral Pharmacology of Cannabis
Interventions
First Posted Date
2022-03-18
Last Posted Date
2024-10-08
Lead Sponsor
Johns Hopkins University
Target Recruit Count
28
Registration Number
NCT05287256
Locations
🇺🇸

Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Phase 2
Recruiting
Conditions
Sleep
Pain
Multiple Sclerosis
Interventions
First Posted Date
2022-03-08
Last Posted Date
2025-03-14
Lead Sponsor
Tiffany J. Braley, MD, MS
Target Recruit Count
166
Registration Number
NCT05269628
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Activation of the Endocannabinoid System and Cognition

Not Applicable
Completed
Conditions
Post Traumatic Stress Disorder
Interventions
First Posted Date
2022-02-07
Last Posted Date
2025-03-10
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
192
Registration Number
NCT05226351
Locations
🇩🇪

Charité Universitätsmedizin Berlin, Berlin, Germany

🇩🇪

Charite University, Berlin, Germany

Influence of Edible Marijuana on Endurance Exercise Performance

Early Phase 1
Completed
Conditions
Endurance Exercise
Interventions
Drug: Placebo
First Posted Date
2022-01-14
Last Posted Date
2024-04-22
Lead Sponsor
Christopher Bell
Target Recruit Count
17
Registration Number
NCT05192239
Locations
🇺🇸

Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, United States

Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio

Not Applicable
Completed
Conditions
Cannabis Use
Interventions
First Posted Date
2021-12-27
Last Posted Date
2021-12-27
Lead Sponsor
King's College London
Target Recruit Count
46
Registration Number
NCT05170217
Locations
🇬🇧

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath